Clinical trial to evaluate the influence of 6 day-dexamethasone (inducer of CES1) co-administration on the pharmacokinetics of oseltamivir in healthy volunteers

Bundang CHA General Hospital0 个研究点目标入组 20 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•1) Subjects who listened to the description about characteristics of this clinical trial and signed the IRB approved consent form before the whole screening tests
•2) Healthy Korean male volunteers who are 20 to 45 years old

•1) Subject who have clinical evidence of significant respiratory, cardiological, nephrological, gastrointestinal, endocrinological, hematological, neurological (included ataxia), psychiatric disorders or other chronic disorders, alcohol or substance addiction
•2) Subjects who take medicine which is known to have significant drug interaction or is judged as inappropriate by researcher within 14 days of administration of drugs for clinical trial
•3) Subjects who donated blood within 30 days from the start of clinical trial or who participated in the clinical trial of other drugs for clinical trials or post marketing surveillance.
•4) Subjects who have experienced significant adverse reactions such as hypersensitivity to drugs for clinical trials
•5) Subjects who planned pregnancy or cannot use established contraceptions (e.g. infertility operation of the subject or partner, intrauterine contraceptive device of the partner, barrier contraception, diaphragm or condom use in combination during the test
•6) Female subject who were pregnant or breast-feeding
•7) Subject who are judged as inappropriate for participating in the clinical trial by researcher because of causes including the test result of clinical laboratory

发起方

Bundang CHA General Hospital